Kindness, not indignation for mask-wearers, please.
We’re living the COVID comeback, but the immunocompromised among us may still need to wear mask. We need to show kindness, not indignation.
top of page
Vocal.
Search
Ulrich Neumann, MBA MSc MA
Feb 10, 20221 min read
Marc Cuban's Cost-Plus
Mark Cuban's latest venture may shift people's perception on the drug supply chain. That's a welcome opportunity to rethink it.
Ulrich Neumann, MBA MSc MA
Jan 26, 20221 min read
CBO report finds claim that drug prices increased "unlikely"
The very latest official CBO report now states unequivocally: It's "unlikely" drug net prices have increased, and they declined in Medicare
Ulrich Neumann, MBA MSc MA
Jan 25, 20221 min read
The majority of "drug spending" isn't really on drugs.
The majority of "drug spending" isn't really on drugs. When it comes to overall spending on pharmaceuticals, only 37% go to manufacturers.
Ulrich Neumann, MBA MSc MA
Dec 23, 20211 min read
CMS: Drug prices are not skyrocketing, they declined in 2020
Per CMS: Drug prices are not skyrocketing on the list price level and they are in fact declining for yet another year on net prices.
Ulrich Neumann, MBA MSc MA
Nov 4, 20211 min read
What if 'negotiation' brought down drug cost...
What would happen if drug price 'negotiation' brought down pharma list prices across the board? Not much at all, at least not for...
Ulrich Neumann, MBA MSc MA
Oct 26, 20211 min read
A $250B healthcare reform opportunity in three years: Reducing administrative complexity
New research by David Cuttler with McKinsey and Partners published in JAMA shows that there are $250B in healthcare savings annually....
Ulrich Neumann, MBA MSc MA
May 29, 20211 min read
Memorial Day Patriotism
From NYC to Texas, the feeling going into this Memorial Day weekend is that we're finally done with COVID. But is the virus done with us?
Ulrich Neumann, MBA MSc MA
Feb 27, 20216 min read
The Increasingly Stormy Waters of US Market Access
The US reimbursement landscape has been shifting rapidly over the last few years. We invited 31 MCO leaders to discuss the key trends.
Ulrich Neumann, MBA MSc MA
Oct 14, 20206 min read
Getting Asset Evaluation Right
Evaluating drug candidates for M&A is of the essential parts of R&D innovation. This article proposes an interdisciplinary approach.
Directly blog
bottom of page